What is Neurocrine Biosciences's provision for contract loss?

Neurocrine Biosciences (NBIX) reported provision for contract loss of $231.30M in Q1 2026.

How has Neurocrine Biosciences's provision for contract loss changed year-over-year?

Neurocrine Biosciences's provision for contract loss increased by 49.6% year-over-year, from $154.60M to $231.30M.

Provision for contract loss

Neurocrine Biosciences Provision for contract loss increased by 2.3% to $231.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 49.6%, from $154.60M to $231.30M.

Analysis

StatementBalance Sheet Statement

SectionOther

First reportedQ4 2024

Last reportedQ1 2026May 5, 2026

Metric ID: other_provision_for_loss_on_contracts

Historical Data

6 periods

	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Value	$144.20M	$154.60M	$175.60M	$237.90M	$226.00M	$231.30M
QoQ Change	—	+7.2%	+13.6%	+35.5%	-5.0%	+2.3%
YoY Change	—	—	—	—	+56.7%	+49.6%

Range$144.20M – $237.90M

CAGR+45.9%

Avg YoY Growth+53.2%

Median YoY Growth+53.2%

Provision for contract loss at Other Companies

IncyteINCY View metric

Frequently Asked Questions

What is Neurocrine Biosciences's provision for contract loss?: Neurocrine Biosciences (NBIX) reported provision for contract loss of $231.30M in Q1 2026.
How has Neurocrine Biosciences's provision for contract loss changed year-over-year?: Neurocrine Biosciences's provision for contract loss increased by 49.6% year-over-year, from $154.60M to $231.30M.